Atria Investments Inc Has $274,000 Stock Holdings in Privia Health Group, Inc. (NASDAQ:PRVA)

Atria Investments Inc grew its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 11.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,014 shares of the company’s stock after acquiring an additional 1,494 shares during the period. Atria Investments Inc’s holdings in Privia Health Group were worth $274,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of PRVA. Nordea Investment Management AB grew its stake in Privia Health Group by 33.1% in the fourth quarter. Nordea Investment Management AB now owns 349,773 shares of the company’s stock valued at $6,953,000 after purchasing an additional 86,910 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Privia Health Group by 402.9% in the 3rd quarter. Victory Capital Management Inc. now owns 179,049 shares of the company’s stock valued at $3,260,000 after buying an additional 143,446 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Privia Health Group by 2.2% in the third quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company’s stock valued at $23,092,000 after buying an additional 28,480 shares in the last quarter. Rhumbline Advisers increased its holdings in Privia Health Group by 1.3% during the fourth quarter. Rhumbline Advisers now owns 287,200 shares of the company’s stock worth $5,615,000 after buying an additional 3,658 shares during the last quarter. Finally, Barclays PLC raised its position in Privia Health Group by 240.3% during the third quarter. Barclays PLC now owns 224,018 shares of the company’s stock worth $4,079,000 after acquiring an additional 158,188 shares in the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

Analysts Set New Price Targets

PRVA has been the subject of a number of analyst reports. Needham & Company LLC lifted their price objective on shares of Privia Health Group from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Stephens reissued an “overweight” rating and set a $26.00 price target on shares of Privia Health Group in a research report on Thursday, January 2nd. JMP Securities set a $29.00 price objective on Privia Health Group in a research note on Friday, February 28th. Macquarie initiated coverage on Privia Health Group in a research note on Monday, December 16th. They set an “outperform” rating and a $25.00 target price for the company. Finally, JPMorgan Chase & Co. increased their price target on Privia Health Group from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Friday, November 29th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $26.67.

Privia Health Group Stock Performance

PRVA opened at $23.24 on Tuesday. The stock has a fifty day moving average of $23.42 and a 200-day moving average of $20.94. The company has a market capitalization of $2.80 billion, a P/E ratio of 232.42, a P/E/G ratio of 3.47 and a beta of 0.85. Privia Health Group, Inc. has a fifty-two week low of $15.92 and a fifty-two week high of $26.04.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.